Moderna mRNA Market Swindle in Progress With New Cancer Press Release
Updated
The year was 2020, and the biopharma industry made a public promise to be transparent and put safety first in their race to develop an mRNA vaccine. Meanwhile, cheap, available, and effective early treatments were being viciously withheld and attacked to prep the runway for the eventual EUA COVID shot.
At the time, Fauci was telling his team at NIAID that getting Moderna’s COVID shot into phase 2 trials was the agency’s “highest priority”:
“To reiterate- getting the Moderna vaccine into Phase 2 trials is the highest priority for the vaccine effort (Quote from Tony Fauci to me this week: ‘I hope that you feel like my foot is on your neck right now to get this done’).” -Emily Erbelding, a deputy director at Fauci’s NIAID
Upon completion of COVID shot trial phases, both Pfizer and Moderna put out sweeping press releases without the actual datasets. “95%” effective, the legacy media sang their praises sans full information.
At the same time, top Pfizer and Moderna officials cashed in – the market pump-and-dump was on, led by untruthful press releases.
Pfizer CEO sold $5.6 million of stock as the company announced vaccine data that sent shares soaring, wrote CNBC.
Upon the press release of its Phase 1 COVID shot trials, Moderna’s CEO Bancel and other executives and funds controlled by the chairman of its board sold about $90 million worth of company shares.
At the time, Kyle Herrig, who heads Accountable.US, penned a letter to the SEC alerting:
”This misconduct was particularly egregious because it involved not only financial fraud and manipulation of the financial markets, but also because it exploited widespread fears surrounding the ongoing COVID-19 pandemic…I strongly urge the SEC to investigate these matters.”
Crickets…
As the fraudulent and failed tide recedes from the pandemic response, one item made it to shore that shouldn’t have…mRNA vaccine technology with still unaccounted-for devastation.
An artificial business space propped up by liability protection and a trail of fraud leading to the genesis of the mRNA market.
In January 2026 Moderna CEO Bancel stated at DAVOS that the U.S. vaccine market rests/thrives on government mandates.
“We’ve said very publicly to our investors that we do not foresee investing in new phase 3 studies in the foreseeable future in vaccines because you cannot make a return investment… because your market is much smaller because you don’t have a recommendation by the government.”
Interestingly, after MAHA’s top 3 FDA officials exited, Moderna was suddenly awarded new mRNA flu shot approval.
History is now repeating itself for Moderna and its mRNA market manipulation. This time, in the newly emerging cancer vaccine space, poised to make the COVID shot revenue look like a mere pittance.
Headlines are now racing about Moderna’s new breakthrough that could usher in a wave of cancer vaccines. There’s only one problem…those headlines are once again being driven by a simplistic, highly curated Moderna press release that doesn’t show the actual data. The stock price didn’t care.
Large swaths of the public know and lived through much of what is written in this article.
Judicial Notice is the formal legal procedure where a judge accepts a universally known or easily verified fact as true without needing witnesses or documents. One could say the harms produced by the mRNA COVID shot and the fraud underpinning its market approval may be approaching judicial notice if a court case commenced.
Do Moderna shareholders and investors know this information?
We do have a recent precedent.
In 2018, Bayer completed its acquisition of Monsanto for $63B, acquiring its flagship cancer-causing crop chemical, glyphosate. The public knew the deal was toxic, as March Against Monsanto protests had been raging globally since 2013. Just one year after Bayer’s acquisition, the headlines looked different.
Bayer’s poor decision led to its CEO having to step down and a major corporate restructuring to address a severe $7.25 billion Roundup litigation.
Last year brought more fallout from the Bayer’s business move as a federal judge granted final approval to a $38 million class action settlement in a case against Bayer over shareholders’ claims the German pharmaceutical giant didn’t conduct adequate due diligence before making a multibillion-dollar deal to acquire Monsanto.
We should be close to this stage for Moderna; however, the medical and scientific community is a different animal.
Namely, the liability protection vaccines have been afforded has hidden both the COVID-era injuries and legacy harms from CDC’s mandated vaccine schedule. In addition, legal discovery in court cases is near zero. U.S. Health and Human Services has had no incentive to do proper safety studies on vaccines because those studies would be used against them in court cases.
The result is an artificial market continually manipulated by poor science and data, while the real-world results of the products are hidden and ignored as they cause harm across the population.
It will take a concerted effort by the Securities and Exchange Commission, the Department of Justice, and Health and Human Services to uproot the embedded, multifaceted aspects of biopharma industry fraud that have been allowed to freely infect American business and culture presently.
Until then, don’t take Moderna’s word for it. Do your own research.